AFRICA: Interview with Dr Jim Kim, director of WHO's HIV/AIDS department 

[This report does not necessarily reflect the views of the United Nations]


NAIROBI, 5 September (IRIN) - 
Dr Jim Kim, Director HIV/AIDS Department, WHOIn 2003 the World Health 
Organisation (WHO) joined UNAIDS and the Global Fund to Fight AIDS, 
Tuberculosis and Malaria to declare the lack of access to antiretroviral (ARV) 
drugs a global health emergency. In response, WHO and its partners launched the 
'Treat 3 Million by 2005' (3 by 5) initiative. IRIN/PlusNews spoke to Dr Jim 
Kim, director of WHO's HIV/AIDS department. 

QUESTION: After the problems seen in Arusha with the Fund's next round and 
donors' apparent reluctance to increase their funding, what guarantees of 
sustainability can mass antiretroviral therapy (ART) have? Are we urging poor 
countries to take on life-or-death commitments that are dependent on erratic 
outside funding? 

ANSWER: Around the world, entire communities face social collapse because of 
the AIDS pandemic. The drive to provide treatment comes from affected countries 
and their leaders. WHO is working with ministries of health to provide 
technical assistance to help scale up treatment.

Because treatment is for life, long-term funding is essential to ensure that an 
entire generation will not be lost to HIV/AIDS. Current resources are the 
result of extraordinary advocacy efforts by communities living with HIV, 
activists, NGOs, faith-based organisations, leadership from heads of state and 
multilateral organisations.

There was nothing automatic about getting the funding we have, and there will 
be nothing automatic about sustaining it but, in my view, this is simply the 
task we are faced with if we are serious about tackling the worst pandemic 
mankind has faced for hundreds of years. Those of us who have the means to 
mobilise at a community, national and international level must do so to ensure 
appropriate resources.

The Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria has been a 
remarkable instrument in galvanising global treatment and prevention of 
HIV/AIDS. Three years ago, the Global Fund was an idea: since then it has 
raised US $3 billion - two-thirds of which is dedicated to HIV/AIDS - and are 
successful in rolling that money out into effective prevention and treatment 
programmes.

The United States President's Emergency Programme for AIDS Relief (PEPFAR) has 
committed $15 billion to AIDS relief globally and is also moving quickly. 
National governments have also increased funding for treatment - the British 
government recently doubled its international AIDS budget. New commitments from 
the World Bank, as well as the private sector and non-governmental, faith-based 
and community organisations, have also emerged.

Six million people living with AIDS need ART now, and this number is growing. 
The '3 by 5' target aims to mobilise the world to treat half of those in need - 
three million by the end of 2005. Continued long-term national and 
international support is essential to continue to move towards reaching the 
target. We simply must recommit ourselves to doing whatever it takes to meet 
the challenges ahead.

Q: To what extent has the recent controversy around generic companies 
withdrawing from the World Health Organisation's prequalification list 
threatened the survival of antiretroviral programmes?

A: What we are talking about here is short-term pain for long-term gain; it is 
about improving the overall quality of medicines for all poor people, not just 
those living with HIV. As drugs are relisted over the next few months, in the 
medium to long term I think we will all conclude that the prequalification 
process will have had a positive affect on scaling up treatment.

The Prequalification project, set up in 2001, is a service provided by WHO to 
facilitate access to medicines that meet unified standards of quality, safety 
and efficacy for HIV/AIDS, malaria and tuberculosis.

Prequalification was originally intended to give United Nations procurement 
agencies, such as UNICEF, the choice of a range of quality medicines. Countries 
most in need of life-saving ARV and other drugs often do not have the 
regulatory capacity to ensure the safety and quality of medicines from 
different suppliers around the world. With time, the growing list of medicines 
that have been found to meet the set requirements has come to be seen as a 
useful tool for anyone purchasing medicines in bulk, including countries and 
other organisations.

Companies wishing to have a product prequalified voluntarily submit a dossier 
to WHO, to allow qualified assessment teams to evaluate its quality, safety and 
efficacy. The manufacturer must also open its manufacturing sites to an 
inspection, comprised of regulatory experts from among 28 of the world's 
leading national regulatory agencies, including experts from Europe, Canada and 
Australia.

Ranbaxy Laboratories Limited informed WHO in November that it was voluntarily 
withdrawing all its antiretrovirals (product dossiers under assessment and all 
prequalified products) from WHO prequalification. This action was taken after 
the company found discrepancies in the documentation relating to proof of the 
products' bioequivalence with originator medicines.

The company has already presented WHO with a plan indicating proposed dates for 
the submission of new study reports for these products - the first study is 
expected to be completed by December 2004. Rather than threatening the survival 
of antiretroviral programmes, this withdrawal seeks to ensure the improvement 
of medicines.

[Information on the practical implications of the withdrawal of the 
above-mentioned products from the list of prequalified products for treatment 
programmes can be accessed on the WHO prequalification project web site, where 
the list of alternative products prequalified by WHO may also be found. 
[http://mednet3.who.int/]

Q: Isn't there a danger that the "positive living" aspect of HIV/AIDS treatment 
- better nutrition, for example - is being lost with all the focus on ART?

A: WHO supports positive living - good nutrition, exercise, etc. - but none of 
those things alone have ever been shown to halt the progression of HIV disease. 
The only intervention that has ever been shown to have a proven impact on 
mortality is ARV therapy. However, there is no question that good nutrition, 
exercise and many other aspects of healthy life can have beneficial effects for 
everyone, especially those living with HIV and AIDS.

Comprehensive programmes that integrate treatment and prevention, as well as 
the promotion of 'positive living', are essential. As access to treatment and 
prevention is increased within countries, health systems and infrastructures 
will be strengthened, which will have wide- reaching effects on improving 
public health services for everyone.

As more people are brought onto treatment, People living with HIV/AIDS visiting 
health centres for their treatment checkups will have increased opportunities 
to consult with a health professional about their overall health. A focus on 
ART does not mean the neglect of other, essential areas of care for [people 
living with HIV/AIDS] PLWHA - rather, it enhances these other areas. 

Q: What do you think are the key components of a successful government rollout 
of ART?

A: The most important component is strong political will and commitment to 
implementing a comprehensive approach to HIV that involves accelerating both 
treatment and prevention. Leaders have the responsibility to stand up to AIDS 
and take the fight forward. We have already seen great progress in terms of 
leadership: we now have nearly $ 20 billion pledged for integrated AIDS 
prevention and care, and more and more countries are committing to scaling up 
treatment and care.

Partnerships and collaboration at country and international level between all 
stakeholders - national authorities, UN agencies, multilateral agencies, 
foundations, non-governmental, faith-based and community organisations, the 
private sector, labour unions and representatives of the community of people 
living with HIV/AIDS - are absolutely essential for successful rollout. 
Everybody has a role to play and all stakeholders need to work together, 
coordinating in line with the 'three ones' principals initiated by UNAIDS for 
one agreed HIV/AIDS action framework that provides the basis for coordinating 
the work of all partners; one national AIDS coordinating authority, with a 
broad-based multi-sector mandate; and one agreed country-level monitoring and 
evaluation system.

WHO works closely with ministries of health and others partners in-country, to 
design national HIV/AIDS plans and to identify existing gaps. Prevention and 
treatment needs differ from region to region, as well as country to country. 
The kind of assistance Belarus needs might be quite different from the needs of 
Swaziland or the Philippines. But what countries are consistently asking for is 
technical assistance to turn funding into national AIDS plans, and to turn 
plans into real programmes for people living with and affected by HIV/AIDS. WHO 
is working with countries to provide this technical assistance, but much more 
collaboration is needed.

Q: Beyond the rhetoric, are people living with HIV and AIDS really considered 
an asset in the response to HIV and AIDS, rather than the source of the problem?

A: HIV is non-discriminatory and can hit anyone at any time and in any walk of 
life. Conversely, PLWHA are absolutely central to the fight against HIV/AIDS 
and, from the beginning, it has been AIDS activists who have pushed society 
towards deeper dialogue and swifter action in fighting AIDS.

PLWHA live in the communities with the most need of prevention, treatment and 
care, and are best equipped to advocate for change. Never before have a group 
of people affected by a disease stood up so loudly and effectively to fight it. 
As ambassadors, PLWHA involved in the fight against HIV/AIDS can help defeat 
the epidemic like no one else.

WHO is involving PLWHA at every level of the drive to reach the '3 by 5' 
target. In November 2004, WHO awarded a $1.5 million contract to the Tides 
Foundation-Collaborative Fund, a global consortium of people living with 
HIV/AIDS, and treatment activists, to help prepare PLWHA for ART. In 
implementing the million-dollar grant, the Tides Foundation-Collaborative Fund 
is supporting more than 30 networks of PLWHA around the world in treatment 
preparedness activities, including treatment literacy projects and civil 
society advocacy initiatives.

The future of health belongs as much in the hands of those affected as those 
who care for them. People living with HIV/AIDS must be involved in all aspects 
of HIV/AIDS programmes and at all levels of decision-making and activity.

December 2004
[ENDS]

 This is non-reply e-mail. Please do not hesitate to contact us at [EMAIL 
PROTECTED]

Principal donors: IRIN is generously supported by Australia, Canada, Denmark, 
ECHO, Japan, Netherlands, Norway, Sweden, Switzerland, the United Kingdom and 
the United States of America. For more information, go to: 
http://www.IRINnews.org/donors

[This item comes to you via IRIN, a UN humanitarian news and information 
service, but may not necessarily reflect the views of the United Nations or its 
agencies. All IRIN material may be reposted or reprinted free-of-charge; refer 
to the copyright page (Http://www.irinnews.org/copyright ) for conditions of 
use. IRIN is a project of the UN Office for the Coordination of Humanitarian 
Affairs.] 

To make changes to or cancel your subscription visit:
http://www.irinnews.org/subscriptions



Subscriber: m-net@mauritanie-net.com
Keyword: AFRICA

U N I T E D  N A T I O N S
Office for the Coordination of Humanitarian Affairs (OCHA)
Integrated Regional Information Network (IRIN) - 


_______________________________________________
M-net mailing list
M-net@mauritanie-net.com
http://mauritanie-net.com/mailman/listinfo/m-net_mauritanie-net.com

Répondre à